thisdrug what a medicine's name tells you

WHO naming stem · suffix · 9 listed names

-dopa

This page was written with AI.

dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors

WHO's definition, quoted as written in the 2024 stem book

6 of 9 names appear in these lists: 6 in the US list (FDA Drugs@FDA) and 2 in the EU central list (EMA); 2 have national brands in at least one EU/EEA country.

Names only. This page is about -dopa as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -dopa. So the letters dopa sit at the end of the name (…dopa).

All 9 names WHO lists under -dopa

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 6 of 9 names appear in these lists: 6 in the US list (FDA Drugs@FDA) and 2 in the EU central list (EMA); 2 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. carbidopa
    US brands: LODOSYN
    in combination: CREXONT with levodopa; DHIVY with levodopa; DUOPA with levodopa; RYTARY with levodopa; SINEMET with levodopa; STALEVO 100 with entacapone + levodopa; STALEVO 125 with entacapone + levodopa; STALEVO 150 with entacapone + levodopa; STALEVO 200 with entacapone + levodopa; STALEVO 50 with entacapone + levodopa; STALEVO 75 with entacapone + levodopa; CARBILEV (discontinued in FDA listings) with levodopa; PARCOPA (discontinued in FDA listings) with levodopa; SINEMET CR (discontinued in FDA listings) with levodopa
    EU (central) brands, in combination: Corbilta with entacapone + levodopa; Hopledo with levodopa; Levodopa/Carbidopa/Entacapone Orion with entacapone + levodopa; Onerji with levodopa; Stalevo with entacapone + levodopa; Numient (withdrawn) with levodopa
  2. ciladopa
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  3. droxidopa
    US brands: NORTHERA
    EU (central) brands: none found
  4. etilevodopa
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  5. foscarbidopa
    US brands, in combination: VYALEV with foslevodopa
    EU (central) brands: none found
  6. foslevodopa
    US brands, in combination: VYALEV with foscarbidopa
    EU (central) brands: none found
  7. levodopa
    US brands: INBRIJA, BENDOPA (discontinued in FDA listings), DOPAR (discontinued in FDA listings), LARODOPA (discontinued in FDA listings)
    in combination: CREXONT with carbidopa; DHIVY with carbidopa; DUOPA with carbidopa; RYTARY with carbidopa; SINEMET with carbidopa; STALEVO 100 with carbidopa + entacapone; STALEVO 125 with carbidopa + entacapone; STALEVO 150 with carbidopa + entacapone; STALEVO 200 with carbidopa + entacapone; STALEVO 50 with carbidopa + entacapone; STALEVO 75 with carbidopa + entacapone; CARBILEV (discontinued in FDA listings) with carbidopa; PARCOPA (discontinued in FDA listings) with carbidopa; SINEMET CR (discontinued in FDA listings) with carbidopa
    EU (central) brands: Inbrija
    in combination: Corbilta with carbidopa + entacapone; Hopledo with carbidopa; Levodopa/Carbidopa/Entacapone Orion with carbidopa + entacapone; Onerji with carbidopa; Stalevo with carbidopa + entacapone; Numient (withdrawn) with carbidopa
  8. melevodopa
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. methyldopa
    US brands: ALDOMET (discontinued in FDA listings)
    in combination: ALDOCLOR-150 (discontinued in FDA listings) with chlorothiazide; ALDOCLOR-250 (discontinued in FDA listings) with chlorothiazide; ALDORIL 15 (discontinued in FDA listings) with hydrochlorothiazide; ALDORIL 25 (discontinued in FDA listings) with hydrochlorothiazide; ALDORIL D30 (discontinued in FDA listings) with hydrochlorothiazide; ALDORIL D50 (discontinued in FDA listings) with hydrochlorothiazide
    EU (central) brands: none found

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Decode another name

Decoded

ciladopa

Listed INNCarries the WHO stem -dopa

  • -dopaend of the nameWHO lists it hereWHO definition: dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors

“ciladopa” is an INN that WHO lists under -dopa in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -dopa (Part II B) and the 9 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy